AMPYRA® Prescription and Service Requests
Share Print

References

  1. Harris Interactive. Experiences with Multiple Sclerosis (MS): Perspectives of People with MS and MS Care Partners [poll]. Poll commissioned by: Acorda Therapeutics, Inc. and the National MS Society. March 25, 2008.
  2. Paltamaa J, Sarasoja T, Leskinen E, Wikström J, Mälkiä E. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil. 2007;88:1649-1657
  3. National Multiple Sclerosis Society.
    http://www.nationalmssociety.org/about-multiple-sclerosis/FAQs-about-ms/index.aspx
  4. A Patient Survey of Mobility and Exercise Issues Among MS Patients [poll]. Poll commissioned by Acorda Therapeutics, Inc. and the Multiple Sclerosis Association of America. February 21, 2008.
  5. AMPYRA (dalfampridine) Extended Release Tablets Prescribing Information & Medication Guide. Acorda Therapeutics, Inc. February 2010.
  6. Data on file. Acorda Therapeutics, Inc.
  7. Herndon RM. Pathology and pathophysiology. In: Burks JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York, NY: Demos Medical Publishing; 2000.
  8. Judge SIV, Lee JM, Bever CT Jr, Hoffman PM. Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehabil Res Dev. 2006;43:111-122.
  9. Augustine GJ. Voltage-dependent membrane permeability. In: Purves D, Augustine GJ, Fitzpatrick D, et al, eds. Neuroscience. 4th ed. Sunderland, MA: Sinauer Associates Inc; 2008.
  10. Waxman SG, Ritchie JM. Molecular dissection of the myelinated axon. Ann Neurol. 1993;33:121-136.
  11. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull. 1989;22:47-52.
  12. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience. 1997;77:553-562.
  13. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS walking scale (MSWS-12). Neurology. 2003;60:31-36.
  14. Bever TC, Jr, Judge SIV. Sustained-release fampridine for multiple sclerosis. Expert Opin Invest Drugs. 2009;18:1013-1024.
  15. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial. Lancet. 2009;373:732-738.
  16. Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005; 11; 232-239.
  17. Cohen JA, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology. 2000;54:802-806.
  18. Coulthard-Morris L. In: Burks JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York: Demos Medical Publishing; 2000:221–290
  19. Shumway-Cook A. Brauer S, Woollacott M. Predicting the Probability for Falls in Community-Dwelling Older Adults Using the Timed Up & Go Test. Physical Therapy 2000; 80; 9; 896-903.
  20. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14:383-390.

Indication

AMPYRA® (dalfampridine) Extended Release Tablets is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

IMPORTANT SAFETY INFORMATION

The use of AMPYRA is contraindicated in the following conditions: History of seizure, or moderate or severe renal impairment.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

Patients should discontinue use of any product containing 4-aminopyridine prior to initiating treatment with AMPYRA in order to reduce the potential for dose-related adverse reactions, including seizures.

Seizures: AMPYRA can cause seizures. The risk of seizures increases with increasing AMPYRA doses. AMPYRA is contraindicated in patients with a prior history of seizure. Discontinue AMPYRA use if seizure occurs.

Renally impaired patients: AMPYRA is contraindicated in patients with moderate or severe renal impairment (CrCl ≤ 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51-80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with AMPYRA.

Urinary tract infections were reported more frequently as adverse reactions in patients receiving AMPYRA 10 mg twice daily compared to placebo.

The most common adverse events (incidence ≥ 2% and at a rate greater than the placebo rate) for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.

The risk of adverse events, including seizures, increases with increasing AMPYRA doses. No additional benefit was demonstrated at doses greater than 10 mg twice daily.

There are no adequate and well-controlled studies of AMPYRA in pregnant women. AMPYRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Safety and effectiveness of AMPYRA in patients younger than 18 years of age have not been established.

Clinical studies of AMPYRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

For more information, please see the complete Prescribing Information, including the Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You may also contact Acorda Therapeutics, Inc. at 1-800-367-5109.

AMPYRA® is a registered trademark of Acorda Therapeutics®, Inc.
AMPYRA® is marketed by Acorda Therapeutics®, Inc and manufactured under license from Alkermes Pharma Ireland Ltd.
© 2011 Acorda Therapeutics®, Inc. All rights reserved.

  is a registered trademark of Acorda Therapeutics®, Inc.

AMP193